|
By gdpawel at 2011-11-25 10:07
|
For some time, clinicians have been grumbling about not having a biomarker for Avastin term or any other anti-angiogenesis compound to better help choose which patients would be most likely to respond, thereby avoiding the need to treat everyone to gain a benefit in a few.
One of the biggest challenges with Vascular Endothelial Growth Factor (VEGFterm) therapy has been the lack of a predictive biomarker.
|
|
read more | 3 comments | 18079 reads
|